Medicines & Healthcare products Regulatory Agency



WHO International Standard 3rd WHO International Standard for Erythropoietin, recombinant, for bioassay NIBSC code: 11/170 Instructions for use (Version 1.0, Dated 30/10/2012)

1. INTENDED USE

The second International Standard (IS) for Erythropoietin (EPO) in ampoules coded 88/574 has been widely used for the calibration of preparations of recombinant DNA-derived EPO by bioassay. Stocks of the 2nd IS are exhausted and the World Health Organization (WHO) Expert Committee on Biological Standardization (ECBS) has recognized (2010) the need for a replacement International Standard for EPO for the assignment of potency to therapeutic preparations of recombinant human EPO used in the treatment of anaemia.

A new preparation of recombinant EPO has been filled into ampoules (NIBSC Code 11/170) and has been characterized by in vivo bioassay in an international collaborative study with expert laboratories and was established as the 3rd International Standard at the 63rd meeting of the ECBS. This material replaces the 2nd IS.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

Each ampoule contains 1650 IU of EPO

4. CONTENTS

Country of origin of biological material: USA.

Each ampoule contains the residue after freeze-drying of 0.5 ml of a solution that contained:

Recombinant human EPO	approximately 11µg
Human serum albumin	0.2 % (w/v)
Trehalose	1.0 % (w/v)
NaCl	0.12 % (w/v)

5. STORAGE

Unopened ampoules should be stored at -20°C. Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufactures instructions provided with the ampoule breaker.

7. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards,

UK Official Medicines Control Laboratory

For practical purposes, each ampoule contains the same quantity of recombinant human EPO. The entire content of each ampoule should be completely dissolved in an accurately measured amount of buffer solution. The use of water to reconstitute ampoule contents is not recommended. The material has not been sterilized and the ampoules contain no bacteriostat.

COLLABORATIVE STUDY

The preparation was evaluated in a collaborative study in which fifteen laboratories in seven countries took part, organized with the following aims:

1) To calibrate the candidate preparation, 11/170 relative to the 2nd IS (88/574) for EPO by in vivo bioassays.

2) To determine the stability of the candidate preparation 11/170 by comparison with ampoules stored at elevated temperatures as part of an accelerated degradation stability study.

The geometric mean potency for the candidate standard was 1648 IU per ampoule (n=15; 95% confidence limits 1562 - 1738; GCV 10.1%)

The candidate preparation 11/170 is sufficiently stable to serve as an International Standard. Analysis of the thermally accelerated degradation samples in this study demonstrated no detectable loss of potency at these elevated temperatures. This suggests that 11/170 is likely to be highly stable under long term storage at -20°C.

8. STABILITY

Reference materials are held at NIBSC within assured, temperaturecontrolled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

It is the policy of WHO not to assign an expiry date to their international reference materials. They remain valid with the assigned potency and status until withdrawn or amended.

In addition, once reconstituted, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

Further information can be obtained from the report of the collaborative study which is available from the WHO website: http://www.who.int/biologicals/en/

10. ACKNOWLEDGEMENTS

We gratefully acknowledge the important contributions of all the participants and the manufacturer of the therapeutic EPO for the kind donation of material.

11. FURTHER INFORMATION

Further information can be obtained as follows; This material: enquiries@nibsc.org WHO Biological Standards: http://www.who.int/biologicals/en/ JCTLM Higher order reference materials: http://www.bipm.org/en/committees/jc/jctlm/ Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx Ordering standards from NIBSC: http://www.nibsc.org/products/ordering.aspx NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx





12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties			
Physical appearance:	Corrosive:	No	
Freeze dried powder			
Stable: Yes	Oxidising:	No	
Hygroscopic: Yes	Irritant:	No	
Flammable: No	Handling:See cau	tion, Section 2	
Other (specify): Contains material of human origin			
Toxicological properties			
Effects of inhalation:	Vot established, avoid inhalation		
Effects of ingestion:	Not established, avoid in	established, avoid ingestion	
Effects of skin absorption:	Not established, avoid c	established, avoid contact with skin	
Suggested First Aid			
Inhalation: Seek medical advice			
Ingestion: Seek medical advice			
Contact with eyes: Wash with copious amounts of water. Seek			
medical advice			
Contact with skin: Wash	noroughly with water.		
Action on Spillage and Method of Disposal			
Spillage of ampoule contents material wetted with an appr appropriate disinfectant follo	should be taken up with priate disinfectant. Rinse red by water.	absorbent area with an	

Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

Country of origin for customs purposes*: United Kingdom
* Defined as the country where the goods have been produced and/or
sufficiently processed to be classed as originating from the country of
supply, for example a change of state such as freeze-drying.
Net weight: 6mg
Toxicity Statement: Non-toxic
Veterinary certificate or other statement if applicable.
Attached: No

National Institute for Biological Standards and Control,

Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biol efstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.

